Veradermics Announces Poster Presentation on Topline Results from Phase 2/3 ‘302’ Study of VDPHL01 at the 2026 World Congress for Hair Research
Veradermics will present positive topline results from its Phase 2/3 '302' study of VDPHL01 at the 2026 World Congress for Hair Research on May 30. The data, originally shared in April, covers Part A of the randomized, double-blind, placebo-controlled trial involving over 500 males with mild-to-moderate pattern hair loss.
Key figures
- Drug Name
- VDPHL01
- Phase Of Trial
- Phase 2/3
- Study name
- Study '302'
- Patent expiry
- 2043
- Patient count
- over 500
- Market size 2028
- $30 billion
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.